Skip to main content
SpringerLink
Log in

Orphan Drugs aus Sicht der forschenden Pharma- und Biotech-Firmen

Orphan drugs from the perspective of research-based pharmaceutical and biotech companies

  • Seltene Erkrankungen
  • Published:
Der Internist Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Author information

Authors and Affiliations

  1. Verband forschender Pharma-Unternehmen, Hausvogteiplatz 13, 10117, Berlin, Deutschland

    Sabine Sydow &  Siegfried Throm

Authors
  1. Sabine Sydow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Siegfried Throm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sabine Sydow.

Ethics declarations

Interessenkonflikt

S. Sydow und S. Throm arbeiten für den Verband forschender Pharma-Unternehmen in Deutschland, dessen Mitgliedsunternehmen auch Orphan Drugs entwickeln.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

J.R. Schäfer, Marburg

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sydow, S., Throm, S. Orphan Drugs aus Sicht der forschenden Pharma- und Biotech-Firmen. Internist 60, 405–410 (2019). https://doi.org/10.1007/s00108-019-0579-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-019-0579-6

Search

Navigation